ID   NCC-CS1-C1
AC   CVCL_E6MD
RX   PubMed=39645627;
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo, Tadashi).
CC   Doubling time: 31 hours (PubMed=39645627).
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Ser (c.394C>A); ClinVar=VCV000375893; Zygosity=Unspecified (PubMed=39645627).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Derived from site: In situ; Chest wall; UBERON=UBERON_0016435.
ST   Source(s): PubMed=39645627
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 9,10
ST   D21S11: 29
ST   D5S818: 8
ST   D7S820: 8,11
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 14,18
DI   NCIt; C121871; Chondrosarcoma, grade 3
DI   ORDO; Orphanet_55880; Chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=39645627; DOI=10.1007/s13577-024-01152-0;
RA   Noguchi R., Ono T., Osaki J., Adachi Y., Iwata S., Shiota Y.,
RA   Yanagihara K., Nishino S., Funada T., Ogura K., Yoshida A., Kawai A.,
RA   Kondo T.;
RT   "Establishment and characterization of a novel patient-derived cell
RT   line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.";
RL   Hum. Cell 38:28.1-28.10(2025).
//